Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGiM trial of darbepoetin alpha with or without G-CSF versus best supportive care in low-risk myelodysplastic syndromes
ISRCTN65652441Phase 3Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Jul 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Darbepoetin alpha, Darbepoetin alpha + G-CSF and Best supportive care (3 arms). Primary endpoint: Quality of life at 24 weeks. Started Jul 2005; status: completed.
02
Drugs
darbepoetin alfafilgrastim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN65652441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65652441.